MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) is advancing a voice-based artificial intelligence platform designed to rapidly detect drug and alcohol impairment from short speech samples, offering a non-invasive alternative to traditional testing methods. The company announced the development of its AI-powered voice analysis technology, which has been trained on more than 50 million data points and analyzes over 140 acoustic markers to deliver real-time impairment assessments.
The technology is being developed for deployment through Edge AI kiosks, with initial field testing planned for 2026. MindBio’s initial commercial focus is on South American mining operations, where large-scale workforce screening presents significant safety and logistical challenges. The platform aims to provide a faster, scalable solution compared to conventional breath, saliva, urine, and laboratory-based tests.
The global alcohol and drug testing devices market is projected to grow from approximately $2.5 billion in 2025 to $4.2 billion by 2033, according to industry data. MindBio sees opportunities to expand its platform into aviation, construction, transportation, law enforcement, call centers, and healthcare, leveraging its proprietary research to address increasing demand for workplace impairment detection.
MindBio is a biotechnology company commercializing AI prediction technologies for drug and alcohol intoxication detection via voice analysis. The AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy using only the human voice. The company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for detection in various environments, including mining, aviation, construction, and law enforcement.
For more information, visit the company’s newsroom at https://ibn.fm/MBQIF.
